Aditxt (NASDAQ:ADTX) Posts Quarterly Earnings Results

Aditxt (NASDAQ:ADTX) announced its quarterly earnings data on Monday. The company reported ($548.78) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.00 million during the quarter. Aditxt had a negative net margin of 206,431.38% and a negative return on equity of 316.98%.

Aditxt Trading Down 3.8%

Shares of Aditxt stock opened at $4.08 on Wednesday. Aditxt has a 12-month low of $4.01 and a 12-month high of $11,941.27. The company has a market cap of $163,200.00, a price-to-earnings ratio of 0.00 and a beta of 1.41. The company’s 50-day moving average price is $56.07 and its 200-day moving average price is $116.65.

Institutional Trading of Aditxt

A hedge fund recently raised its stake in Aditxt stock. IFP Advisors Inc raised its position in Aditxt, Inc. (NASDAQ:ADTX) by 66,926.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,054 shares of the company’s stock after purchasing an additional 10,039 shares during the period. IFP Advisors Inc owned 17.64% of Aditxt worth $45,000 at the end of the most recent reporting period. 15.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aditxt in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aditxt has an average rating of “Sell”.

Aditxt Company Profile

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.